VIJAYA
Vijaya Diagnostic Centre Limited
Healthcare · Diagnostics & Research
Market price data is delayed by at least 15 minutes. Not for trading or investment decisions.
Fundamentals
Current Price
₹975.1
P/B Ratio
11.59
52W High
₹1,180
52W Low
₹848
Dividend Yield
21.00%
Profit Margin
20.73%
ROE
—
Debt / Equity
0.42
Sector
Healthcare
Industry
Diagnostics & Research
Peer Comparison same NSE industry · top 10 by 1M return
Hospital Healthcare Servicesas of 9 Apr 2026 close
| Symbol | Company | Price | P/B | RSI | 1M Ret | ROE | D/E |
|---|---|---|---|---|---|---|---|
| VIJAYAyou | Vijaya Diagnostic Centre Lim | ₹975.1 | 11.59 | 57.8 | +3.2% | — | 0.42 |
| GAUDIUMIVF | Gaudium IVF and Women Health | ₹89.17 | 11.82 | 52.9 | +15.4% | — | — |
| MEDIASSIST | Medi Assist Healthcare Servi | ₹353.7 | 4.29 | 60.7 | +11.9% | — | 0.52 |
| RAINBOW | Rainbow Childrens Medicare L | ₹1,254 | 8.39 | 72.1 | +6.0% | — | 0.53 |
| LAXMIDENTL | Laxmi Dental Limited | ₹190.22 | 4.45 | 61.3 | +5.3% | — | 0.04 |
| THYROCARE | Thyrocare Technologies Limit | ₹392.9 | 11.69 | 62.2 | +5.0% | — | 0.05 |
| YATHARTH | Yatharth Hospital & Trauma C | ₹704.6 | 4.02 | 60.9 | +3.4% | — | 0.02 |
| SHALBY | Shalby Limited | ₹150.85 | 1.63 | 58.6 | +3.3% | — | 0.53 |
| LALPATHLAB | Dr. Lal Path Labs Ltd. | ₹1,395.2 | 9.75 | 65.0 | +1.2% | — | 0.06 |
| ASTERDM | Aster DM Healthcare Limited | ₹668.1 | 7.61 | 50.4 | +0.8% | — | 0.44 |
| SANOFICONR | Sanofi Consumer Healthcare I | ₹4,568.8 | 27.41 | 62.8 | +0.7% | 73.1% | 0.06 |
Price Chart
Quarterly Results Last 4 quarters
| Metric | 2025-12 | 2025-06 | 2025-03 | 2024-12 |
|---|---|---|---|---|
| Revenue | ₹205.2 Cr | ₹188.1 Cr | ₹172.8 Cr | ₹169.0 Cr |
| Gross Profit | ₹181.2 Cr | ₹166.6 Cr | ₹150.6 Cr | ₹148.1 Cr |
| Operating Income | ₹61.7 Cr | ₹52.6 Cr | ₹50.0 Cr | ₹48.8 Cr |
| Net Income | ₹43.2 Cr | ₹38.3 Cr | ₹34.6 Cr | ₹35.3 Cr |
Values in INR Crore. Source: yfinance / NSE filings.
SWOT Analysis AI · news + fundamentals
SWOT not available.
Recent News Sentiment
No recent news for this stock.
Data sourced from yfinance and public NSE filings. Not investment advice.